Key result
Resveratrol significantly improved left ventricular ejection fraction (WMD 17.88) and other cardiac function and oxidative stress markers in animal models of diabetic cardiomyopathy.
Why the study?
Animal studies indicated that resveratrol enhances cardiac function in diabetic cardiomyopathy, but its reliability and underlying mechanism remained unclear.
Does resveratrol improve cardiac function in animal models of diabetic cardiomyopathy?
Meta-Analysis (n=363)
Does resveratrol improve cardiac function in animal models of diabetic cardiomyopathy?
Mean Difference: 17.88 (95% CI 8.15–27.61)
p-value: p=0.0003
In preclinical models of diabetic cardiomyopathy, resveratrol improves cardiac function and reduces oxidative stress, suggesting potential as a future therapeutic agent.
Resveratrol merits human trials in diabetic cardiomyopathy; extends meta-analytic confirmation of preclinical cardiac benefits.
Introduction Diabetic cardiomyopathy (DCM) is a significant complication of diabetes, characterized primarily by the development of heart failure in individuals with diabetes. Numerous animal studies have indicated that resveratrol enhances cardiac function in diabetic cardiomyopathy; however, its reliability and underlying mechanism remain unclear. This study aims to assess the cardioprotective effects of resveratrol on DCM and explore its potential mechanism. Methods We searched PubMed, EMBASE, WOS, Cochrane Library, CNKI, CBM, Chinese VIP, and Wan Fang Database until March 31st, 2024, without language restrictions. Continuous outcome measures were analyzed using weighted mean difference or standardized mean difference, and heterogeneity was assessed with I 2 . The risk of bias in animal experiments was evaluated using the SYRCLE tool, and evidence reliability was determined with the GRADE tool. All data were analyzed using Review Manager 5.4.1 and Stata 17. This study has been registered on the PROSPERO (CRD42024523944). Results A total of 18 studies meeting the criteria were identified. The analysis revealed that the resveratrol intervention group exhibited significant improvements in LVEF (WMD = 17.88), LVFS (WMD = 8.77), HW/BW (SMD=-2.92), SOD (SMD = 4.53), and MDA (SMD=-5.07) compared to the control group. The GRADE grading assessment indicated moderate certainty for LVEF, HW/BW, and MDA, while certainty for other factors was considered low. Conclusion Our research suggests that resveratrol may protect cardiac function in DCM through anti-inflammatory and anti-oxidative stress effects. However, these findings are based on preclinical data, and further extensive trials are needed to confirm their effectiveness and safety before clinical application.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2024) conducted a meta-analysis in Diabetic cardiomyopathy (n=363). Resveratrol vs. Untreated or placebo control was evaluated on Left Ventricular Ejection Fraction (LVEF) (WMD 17.88, 95% CI 8.15-27.61, p=0.0003). Resveratrol significantly improved left ventricular ejection fraction (WMD 17.88) and other cardiac function and oxidative stress markers in animal models of diabetic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: